330 related articles for article (PubMed ID: 29664016)
21. Update on PARP Inhibitors in Breast Cancer.
Zimmer AS; Gillard M; Lipkowitz S; Lee JM
Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491
[TBL] [Abstract][Full Text] [Related]
22. The DNA damaging revolution.
Cetin B; Wabl CA; Gumusay O
Crit Rev Oncol Hematol; 2020 Dec; 156():103117. PubMed ID: 33059228
[TBL] [Abstract][Full Text] [Related]
23. Poly(ADP-Ribose) Polymerase Inhibitors for Arsenic Trioxide-Resistant Acute Promyelocytic Leukemia: Synergistic In Vitro Antitumor Effects with Hypomethylating Agents or High-Dose Vitamin C.
Giansanti M; De Gabrieli A; Prete SP; Ottone T; Divona MD; Karimi T; Ciccarone F; Voso MT; Graziani G; Faraoni I
J Pharmacol Exp Ther; 2021 Jun; 377(3):385-397. PubMed ID: 33820831
[TBL] [Abstract][Full Text] [Related]
24. Molecular imaging of PARP in cancer: state-of-the-art.
Filippi L; Urso L; Frantellizzi V; Marzo K; Marzola MC; Schillaci O; Evangelista L
Expert Rev Mol Diagn; 2023; 23(12):1167-1174. PubMed ID: 38009232
[TBL] [Abstract][Full Text] [Related]
25. The current status of PARP inhibitors in ovarian cancer.
McLachlan J; George A; Banerjee S
Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
[TBL] [Abstract][Full Text] [Related]
26. Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data.
Arend RC; O'Malley DM; Banerjee S; McLaurin K; Davidson R; Long GH
Adv Ther; 2022 Jan; 39(1):328-345. PubMed ID: 34727316
[TBL] [Abstract][Full Text] [Related]
27. The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
Moore KN; Mirza MR; Matulonis UA
Gynecol Oncol; 2018 Apr; 149(1):214-220. PubMed ID: 29397193
[TBL] [Abstract][Full Text] [Related]
28. Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer.
Musella A; Bardhi E; Marchetti C; Vertechy L; Santangelo G; Sassu C; Tomao F; Rech F; D'Amelio R; Monti M; Palaia I; Muzii L; Benedetti Panici P
Cancer Treat Rev; 2018 May; 66():7-14. PubMed ID: 29605737
[TBL] [Abstract][Full Text] [Related]
29. PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers.
Ali R; Alabdullah M; Alblihy A; Miligy I; Mesquita KA; Chan SY; Moseley P; Rakha EA; Madhusudan S
Cancer Lett; 2020 Jan; 469():124-133. PubMed ID: 31669203
[TBL] [Abstract][Full Text] [Related]
30. Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials.
Ruscito I; Bellati F; Ray-Coquard I; Mirza MR; du Bois A; Gasparri ML; Costanzi F; De Marco MP; Nuti M; Caserta D; Pignata S; Dorigo O; Sehouli J; Braicu EI
Cancer Treat Rev; 2020 Jul; 87():102040. PubMed ID: 32485510
[TBL] [Abstract][Full Text] [Related]
31. PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review.
Cook SA; Tinker AV
BioDrugs; 2019 Jun; 33(3):255-273. PubMed ID: 30895466
[TBL] [Abstract][Full Text] [Related]
32. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
[No Abstract] [Full Text] [Related]
33. Kinetic and Static Analysis of Poly-(Adenosine Diphosphate-Ribose) Polymerase-1-Targeted
Young AJ; Pantel AR; Viswanath V; Dominguez TL; Makvandi M; Lee H; Li S; Schubert EK; Pryma DA; Farwell MD; Mach RH; Simpkins F; Lin LL; Mankoff DA; Doot RK
J Nucl Med; 2022 Jan; 63(1):44-50. PubMed ID: 33863820
[TBL] [Abstract][Full Text] [Related]
34. Associations between pharmaceutical industry payments to physicians and prescription of PARP inhibitors in the United States.
Murayama A; Marshall DC
Gynecol Oncol; 2024 Feb; 181():83-90. PubMed ID: 38147713
[TBL] [Abstract][Full Text] [Related]
35. PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date.
Nizialek E; Antonarakis ES
Cancer Manag Res; 2020; 12():8105-8114. PubMed ID: 32982407
[TBL] [Abstract][Full Text] [Related]
36. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
[TBL] [Abstract][Full Text] [Related]
37. The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy.
Maiorano BA; Lorusso D; Maiorano MFP; Ciardiello D; Parrella P; Petracca A; Cormio G; Maiello E
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409229
[TBL] [Abstract][Full Text] [Related]
38. Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials.
Fan L; Zhang Y; Maguire P; Muston D; Monberg M; Earla JR; Mihai A; Gulati P
J Mark Access Health Policy; 2022; 10(1):2078474. PubMed ID: 35693379
[TBL] [Abstract][Full Text] [Related]
39. PARP inhibitors in ovarian cancer.
Ledermann JA
Ann Oncol; 2016 Apr; 27 Suppl 1():i40-i44. PubMed ID: 27141070
[TBL] [Abstract][Full Text] [Related]
40. Trapping Poly(ADP-Ribose) Polymerase.
Shen Y; Aoyagi-Scharber M; Wang B
J Pharmacol Exp Ther; 2015 Jun; 353(3):446-57. PubMed ID: 25758918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]